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Background

28
In recent decades the Western diet has dramatically changed, being now characterized by 29 high amounts of processed foods, refined sugars, refined fats and oils. This dietary shift has M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
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Firmicutes and Proteobacteria), (Bourdichon et al., 2012) , with 22 of them represented by 93 strains that are patented in Europe due to their potential probiotic properties (Table 1) .
94
Despite their particular relevance, exploiting lactobacilli has always been very challenging 95 due to their unusual phenotypic and genotypic diversity, unclear species identity and 96 uncertain degree of relatedness between them and other commercially important lactic acid 97 bacteria (Sun et al., 2015) .
98
In 2015, the genome sequences of almost all Lactobacillus type strains and some historically 99 associated genera were determined (Sun et al., 2015; Zheng et al., 2015) , thus providing a 100 definitive genomic resource for mining all relevant phylogenetic and functional information.
101
This data repository should also prove useful for understanding the species-restricted 102 distribution of probiotic traits, thus supporting probiotic claim substantiation.
103
Despite the unprecedented availability of genome sequences and increasing functional 104 information about lactobacilli, the development of functional products containing these 
Taxonomic characterization of Lactobacillus probiotics
111
Isolation and the full characterization of a candidate probiotic is the first essential 112 requirement for a novel food marketing authorization and a health claim submission (EFSA, 113 2017; EFSA 2016b). The taxonomic determination of the genus, the species and the strain 114 contained in a probiotic product provides useful preliminary information regarding the main 115 physiological and metabolic properties of the organism, and allows its discrimination from 116 other closely related but potentially non-beneficial strains (ILSI 2013) .
117
The ideal characterization of microorganisms should include both genotypic and phenotypic 118 tests; the combination of these data strands allows identity of the microorganism at both the 119 species and strain level (EFSA, 2015) .
120
Taking account of the current state-of-the-art techniques for identification and molecular 121 characterisation of microorganisms, EFSA recommends sequence analysis of at least two 122 robust taxonomic markers (i.e. 16S rRNA gene sequence) or fully assembled and validated 123 whole-genome sequence analysis for species identification. Genome sequencing is also 124 suggested for strain typing, but this can also be achieved by other internationally accepted 125 genetic typing molecular methods like whole genome mapping (WGM) or optical mapping
analysis. The bacterium is considered to be sufficiently characterised only when these two 127 criteria are fulfilled. In addition, the EFSA advocates that the strain is deposited in at least 128 one recognised international culture collection and encourages naming of strains according to 129 the International Code of Nomenclature (EFSA, 2016b) .
130
The widespread use and characterization of lactobacilli are both hindered by the complex 131 taxonomic structure of the genus, reflected in a poor correlation between the phylogenetic 132 relationship and the physiological properties of Lactobacillus species (Zheng et al., 2015) .
133
Moreover, the ongoing description of novel species, whose number increased from 152 134 (Salvetti et al., 2012) housekeeping genes as pheS, rpoA (Naser et al., 2007) and recA (Torriani et al., 2001 ) have 144 been used as alternative phylogenetic markers which provide a higher discrimination between 145 lactobacilli. Although the application of these molecular markers offers useful potential in the 146 probiotic field, data interpretations by taxonomic experts remains crucial to ensure reliability 147 of the identification results (Sanders et al., 2010) .
148
When the genomes of the type strains of around 175 Lactobacillus species were recently 149 sequenced (Sun et al., 2015; Zheng et al., 2015) , the ensuing analysis of the Average displaying a level of genomic diversity that is larger than that which is typical for a 154 taxonomic family (Sun et al., 2015) . Thus the (currently defined) genus Lactobacillus 155 presents problems for strain and species distinction at short phylogenetic range, and problems
156
for clade distinction at long phylogenetic range. None of this has aided providing industries, some notable re-naming of high-profile strains such as La1 (Ashraf and Shah, 2014) .
The vast genomic diversity of the genus Lactobacillus and its polyphyletic structure strongly 160 suggests to us the necessity for the formal revaluation of its taxonomic scheme and its 161 feasibility to be split in more homogeneous genera (Sun et al., 2015; Salvetti et al., 2012) .
162
The creation of more uniform taxonomic nuclei within the Lactobacillus genus is also 163 expected to help prevent mis-identification issues which are still the major cause of 164 mislabelling of probiotic food products reported worldwide (Hill et al., 2016 
205
The approach adopted shall consist primarily of human studies and according to a hierarchy The lack of sufficient efficacy data has undermined the acceptance of health claim dossiers: (http://ec.europa.eu/nuhclaims/) (Glanville et al., 2015) .
216
In addition, successful probiotic claim substantiation is also impeded by EU laws which do 217 not recognise the possibility that food can prevent, treat or cure a disease, leaving scientists, 218 marketers, food producers and also legislators in an ambiguous impasse (Katan et al., 2012) .
219
In a recent attempt to solve these issues, EFSA released updated general scientific guidance 220 for stakeholders on health claim applications in which the Panel on Dietetic Products,
221
Nutrition and Allergies (NDA) outlines the principles to be applied for the scientific 222 evaluation of health claim applications and the issues to be considered by applicants for the 223 compilation of applications (EFSA, 2017; EFSA, 2016b) . Lactobacillus strains) (Figure 1 ).
241
The most numerous species among these applications are Lb. plantarum (28%), Lb. 
262
In this framework, the genome of Lactobacillus type strains (Sun et al., 2015) The development of such a strategy allows predictive modelling of optimal industrial 276 conditions to be used, facilitating the selection and optimization of probiotics and/or 277 beneficial compounds production (Saulnier et al., 2011) .
279
Safety assessment of Lactobacillus species
280
The safety of probiotics is linked to their intended use, the potential vulnerability of the 281 consumer or patient, the dose and duration of consumption and both the manner and 282 frequency of administration.
283
In the EU, a priori safety is generally accepted for microorganisms that have been awarded effects (such as genotoxicity and platelet aggregation) (Miquel et al., 2015) .
301
It is evident that the lack of the mechanistic understanding of probiotic activity together with 302 incorrect species identification and mislabelling of probiotics (discussed above) is a major 303 drawback for the prediction of safety of a probiotic intervention and for the creation of an 304 exhaustive list of criteria to be assessed (Sanders et al., 2010) .
305
Due to these shortcomings, the biological relevance of the requirements listed above is still 306 the subject of debate and no formal guidance exists for the safety assessment of probiotic 307 bacteria (Miquel et al., 2015) .
308
As already mentioned, the majority of Lactobacillus species have a long history of apparently proteins is associated with some virulence loci in pathogens).
357
To tackle this particular issue in future, the availability of the genome sequences of all
358
Lactobacillus type strains will be an invaluable resource for the forensic detection of bona as the decarboxylase activity linked with biogenic amines production compared to genomic 364 searches for the relevant determinants can provide a more robust body of knowledge upon 365 which more specific databases for the analysis of the safety of lactobacilli can be developed.
366
In addition to supporting researchers and scientists in achieving much more consistent data 367 on Lactobacillus safety, these tools can also help regulatory agencies to define more precise 
Lactobacillus rhamnosus 10%
Lactobacillus paracasei 11%
Lactobacillus fermentum 4%
Lactobacillus plantarum 28% Lactobacillus helve cus 4%
Lactobacillus acidophilus 8%
Lactobacillus crispatus 3%
Lactobacillus gasseri 5%
Lactobacillus delbrueckii 6%
Lactobacillus casei 10%
Lactobacillus reuteri 3%
Lactobacillus salivarius 3%
Lactobacillus johnsonii 3% Lactobacillus coryniformis 1%
Lactobacillus brevis 1%
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